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Background: Even though the systemic level of SCCA1, a serine protease inhibitor, was shown
to be elevated in asthma, its physiological role is unknown.
Objective: We sought to determine the effect of SCCA1 on apoptosis, cytokine expression and
mucus production by A549 cells and define the effect of promoter variants on gene expression
and association with asthma.
Methods: SCCA levels were measured by ELISA. Promoter variants were determined by direct
sequencing. 442 asthmatic children and 191 controls were genotyped by RFLP. The functional
effect of the polymorphisms was assessed in transient transfection experiments using reporter
constructs. A transcription factor ELISA was used for differential binding of GATA proteins to
the variant region. The effects of SCCA1 on cytokine synthesis, mucus production and
apoptosis were determined in A549 cells transfected with SCCA1 pcDNA vector. MUC5AC
expression in A549 cells was determined with RT-PCR.
Results: SCCA1 protein level was significantly higher in asthmatic children compared to
healthy controls. Four polymorphisms SCCA1 promoter that were in linkage disequilibrium
were associated with skin test positivity in asthmatic children and showed higher promoter
activity and higher binding of GATA-2 and GATA-3 after IL-4 þ IL-13 stimulation. IL-6, IL-8 levels
were significantly higher in cells transfected with SCCA1 whereas RANTES increased only after
IL-4 stimulation. Transfection of A549 cells with SCCA1 resulted in decreased MUC5AC expres-
sion and conferred protection against apoptosis.33 727 6459; fax: þ90 312 441 95550.
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The role of squamous cell carcinoma antigen 1 in asthma 369Conclusion: Our results showed that SCCA1 has diverse effects on many of the cellular events
that characterize asthma and its role extends beyond protease inhibition.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
The pathogenesis of asthma is incompletely understood. In
addition to cytokines,1,2 chemokines3 and oxidants,4
proteases acting through membrane receptors and the
counteraction by anti-proteases may be important in the
pathogenesis of asthma.5-7
Proteases can be exogenous such as allergens and
various microorganisms or endogenous such as thrombin,
plasmin, cathepsin G, elastase, tryptase and chymase.6e11
Proteases act through Protease-Activated Receptors
(PARs) which are expressed on almost all cell types. In
addition to their roles in coagulation and homeostasis, they
stimulate inflammatory and resident cells in the airways,12
disrupt tight junctions,13 increase secretion of proin-
flammatory cytokines,14 aggravate airway remodeling15 and
increase bronchial smooth muscle contraction16 which
make them critical for the inflammatory diseases of the
airways.
To fight against the proteolytic injury, the human body is
equipped with many protease inhibitors. They have
important roles in the regulation of proteolytic events such
as fibrinolysis and coagulation as well as apoptosis and
inflammation.17,18 Squamous cell carcinoma antigens
(SCCAs) belong to the superfamily of high molecular weight
serine and cysteine protease inhibitors. There are two
tandemly arranged genes known as SCCA1 and SCCA2.
SCCA1 and SCCA2 genes are also known as SERPINB3 and
SERPINB4, respectively and both are located at 18q21.3.
Although these two genes have high homology, they have
distinct biological activities.19 SCCA1 inhibits cysteine
proteases such as cathepsin K, L, S and papain whereas
SCCA2 inhibits serine proteases such as cathepsin G and
human mast cell chymase.20 Even though SCCAs were
initially discovered as a marker of cervical carcinoma, its
levels were subsequently found to be elevated not only in
other carcinomas21,22 but also in atopic dermatitis and
psoriasis.23,24
A role for SCCA in asthma was initially suggested by
a microarray analysis of human bronchial epithelial cell
cultures after stimulation with IL-4 and IL-13. Subsequently
its systemic levels were reported to be increased in
asthma,25 asthma exacerbation25,26 and in patients with
allergic rhinitis.27
Even though there is some evidence that SCCA may be an
important molecule in asthma, its specific role, the mech-
anisms and the genetic associations remain to be eluci-
dated. We have undertaken a comprehensive study to
investigate the role of SCCA in asthma. In the genetic arm,
we searched for single nucleotide polymorphisms (SNPs)
that may influence the transcription of SCCA and performed
association studies. Physiologically, we aimed to determine
the effect of SCCA1 on apoptosis and mucus and cytokine
production by bronchial epithelial cells.Materials and methods
Children with asthma
The patients in the asthma group have been detailed pre-
viously.28e30 Children aged 6e18 years who were diagnosed
with asthma at the Pediatric Allergy and Asthma Unit of
Hacettepe University, School of Medicine, Ankara, Turkey
have been included in the study. Asthma diagnosis was
confirmed according to GINA guidelines.31 Skin testing was
performed as detailed previously.30
Healthy children
Control group has been detailed previously30 and was
composed of Turkish school children who presented to the
outpatient department of the same hospital. They pre-
sented for reasons such as minor trauma or for their regular
follow-up. They responded negatively to an established and
validated asthma questionnaire (ISAAC),32 never had any
diagnosis of asthma, and never had any history of wheezing.
They all had normal pulmonary function tests. All children
underwent skin prick testing and had their total IgE
measured in serum.
Study procedures were approved by the Ethics
Committee of Hacettepe University. All parents provided
written informed consent for the study.
Serum levels of SCCA1 and SCCA2
Serum samples were concentrated five times by SpeedVac
vacuum concentrator (Labconco, Kansas City, MO, USA).
SCCA1 and SCCA2 levels were determined by ELISA (Fujir-
ebio Diagnostic, Malvern, PA, USA).
Identification of genetic variants of SCCA1 and
SCCA2 genes
DNA was extracted from whole blood by standard tech-
niques. Promoter region of SCCA1 and SCCA2 gene was
defined according to the latest sequencing revealed by
genome databases, Ensembl and NCBI.33,34 To determine
the polymorphisms in the promoter and 50 UTR region of the
transcript, DNA samples from 25 asthmatic patients and 25
healthy individuals were amplified by specific primers:
SCCA1 forward: 50-TGCTAAATGGAAGGACCACCA-30, reverse:
50-AGGTGGGCAGAGAGGCTA-30; SCCA2 forward: 50-
TGCTAAACAGAAGGACCATTG-30, reverse: 50-AGGTG GGCA-
GAGA GGCTG-30. Sequencing reaction was performed with
Big Dye Terminator cycle sequencing kit (3.2 version) using
ABI Prism 310 Sequence Detection System (Foster City, CA,
USA). As the initial results suggested the presence of
linkage disequilibrium among four SNPs in the SCCA1
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further sequenced to confirm or refute the observation.
Genotyping for promoter polymorphisms in SCCA1
Sequencing of 250 samples showed that four SNPs in the
SCCA1 promoter were in perfect linkage disequilibrium.
rs116864116 A/G variation was chosen to determine the
genotype by restriction fragment length polymorphism
(RFLP) analysis. A 549 base pair of the promoter region was
amplified using the following primer pairs: forward 50-
AGACATACCTGAGATTAGGA-30 and reverse 50-TTTCTGTA-
TAACAAGGAATA-30. The amplicon was digested with Alw26 I
(New England Biolabs, MA, USA). The products were frac-
tionated on 2% agarose gel. Digestion occurred in the
presence of the A allele and produced a 169 and 380 base
pair products.
Genotyping for the promoter polymorphism in
SCCA2
The genotyping of the SNP rs3760573 (G/T) in SCCA2
promoter was done by PCR-RFLP. However, since there was
no enzyme recognition site, a restriction site for Eco31I
was introduced using a primer containing mismatched
bases adjacent to the SNP. Two sequential PCR reactions
were performed. In first amplification, following SCCA2
specific primer pairs were used: forward 50-AGGTGGGCAGA
GAGGCTG-30 and reverse 50-TGCTAAACAGAAGGACCATTG-
30. In the second, nested PCR was carried out by using first
reaction as a template with internal primers: forward 50-
TATGCTATAAGATACTGAAGTAC-30; mismatch reverse
primer 50-CAGCTGTAAAACAAAAACGAGA-30. The 249 bp
amplicon from nested PCR was then subjected to Eco31I
restriction endonuclease digestion (New England Biolabs).
Digestion occurred with G allele and produced 22 and 227
base pairs.
Cell culture
A549 cells were purchased from DSMZ Company (DSMZ,
Braunschweig, Germany). Cells were grown in 1640 RPMI
(GIBCO BRL, Grand Island, NY, USA) supplemented with 10%
fetal bovine serum, 100 U/ml penicillin and 100 mg/ml
streptomycin in 5% CO2 atmosphere at 37
C. IL-4 (Bio-
source, Camarillo, CA, USA), and IL-13 (CYTOLAB, Pepro-
tech EC Ltd., London, UK) were used at a concentration of
25 ng/ml each in all experiment. All cell culture experi-
ments were performed at least three times with three
samples.
Transient transfection analysis with reporter
constructs
Genomic DNA from individuals bearing four SNPs or wild
type haplotypes was amplified to include 1000 base pairs
upstream from the transcription start site of the SCCA1
promoter. Purified PCR products were cloned into pGL3
basic vector (Promega, Madison, WI, USA) between Kpn I
and Xho I sites (New England Biolabs).A549 cells were used for transfection assays. They were
grown to 90% confluence in 24 well plates, transiently
transfected with either promoter reporter constructs or
empty vectors and co-transfected with pRL-TK vector
containing Renilla Luciferase gene (Promega) using Lip-
ofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according
to the manufacturer’s instructions. A549 cells were treated
with IL-4 or IL-13 or both. 48 h after transfection, cells were
lysed with reporter lysis buffer and luciferase activity of
each lysate was determined using Dual Luciferase Assay kit
(Promega). Firefly luciferase activity was normalized to
renilla luciferase activity to control for differences in
transfection efficiency.
Transcription factor ELISA
Putative transcription factor binding sites were predicted
using TRANSFAC-Biobase Biological Database software
(Biobase Biological Database MA, USA). A549 epithelial cells
were cultured in RPMI medium. Nuclear extracts were
prepared from stimulated (IL-4 and IL-13, 25 ng/ml for 24 h)
and unstimulated A549 cells as described.35 Protein
concentrations of the nuclear extracts were measured
using Bradford Assay (Bio-Rad, Hercules, CA, USA). Double-
stranded, 37 base pair biotin labeled oligonucleotides (IDT,
Coralville, IA, USA) with and without the polymorphisms
were synthesized: SCCA1 wild type primer 50 ACCCCTA
ATAAACCCATTGGATCTCCTGAGACTTATT 30 and SCCA1
mutant type primer 50 ACCCCTGTAAACCCATCGGATCTCCT
GAGGCTTATT 30. Experiment was done according to the
manufacturer’s protocol with a little modification (Active
Motif, Carlsbad, CA). Plates were coated with biotin
labeled double stranded oligonucleotides with and without
mutations followed by incubation with 5 mg of nuclear
extracts for 1 h. The wells were then washed and incubated
with GATA-1, GATA-2 or GATA-3 antibodies. The reaction
was developed with an anti-IgG HRP conjugate and the
colorimetric reaction was measured using a microplate
reader (Molecular Devices, Sunnyvale, CA, USA) at 450 nm.
The experiment was performed in triplicate for each
condition.
Cytokine measurements
A549 cells were seeded in 24 well culture dishes and 24 h
later cells were transiently transfected with SCCA1 pcDNA
full length expression vector (a kind gift by Dr. Sule Cata-
ltepe, Brigham and Women’s Hospital, Harvard Medical
School, MA, USA) using lipofectamine 2000 reagent. After
transfection, cells were stimulated with a combination of
IL-4 and IL-13. 48 h after transfection, supernatants were
collected and stored at 80 C until measurement. Trans-
fection efficiency was proven before each experiment.
The concentration of IL-1b, INF-g, IL-6, IL-8, IL-10, IL-12
and RANTES were measured using ELISA (PIERCE, Thermo
Fisher Scientific, Rockford USA).
Efficiency of transfection
Efficiency of transfection with the SCCA1 expression vector
was determined both by a PCR based method and western
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out from transfected and untransfected cells and isolated
samples were amplified by T7 forward primer specified for
pcDNA vector and reverse primer of SCCA1 gene. Forward
primer sequence is 50 TAATACGACTCACTATAGGG 30 and
reverse primer is 50 GGGATGAGAATCTGCCAT AG 30.
In the western blot method, cells transfected and
untransfected with SCCA1 pcDNA were lysed in buffer
containing 0.5% Triton X-100, 100 mM NaCl, 1 mM EDTA,
20 mM TriseHCl (pH 7.4) and protease inhibitor cocktail
(Roche Applied Science, Indianapolis, IN, USA). Total
protein concentration was calculated by the Bradford
method. Western blot analysis was performed as described
previously.36 Mouse anti human SCCA1 antibody (Abcam,
Cambridge, MA, USA) was performed at 4 C overnight at
the 1/16,000 dilution and recombinant SCCA1 protein
(Abnova, Walnut, CA, USA) was used as a positive control.
Measurement of MUC5AC expression
A549 cells were transfected with SCCA1 pcDNA vector.
Transfected and untransfected cells were left unstimulated
or stimulated with IL-4 and IL-13 (25 ng/ml) and neutrophil
elastase (200 mM) for 24 h. Total RNA was isolated using
RNeasy mini kit (Qiagen, Valencia, CA, USA). One micro-
gram of total RNA was reverse transcribed using ImProm-II
Reverse Transcription System (Promega, Madison, WI).
MUC5AC gene was amplified as described before.37 Inten-
sity of amplification bands were measured by image
analyzer (Syngene Gene Genius, Synoptics, Cambridge, UK)
using Gene Tools Image Analysis Software 3.02.00 (Synop-
tics). Expression of MUC5AC gene in unstimulated samples
was arbitrarily defined as 1 and expression index of other
conditions calculated relative to unstimulated cells.
Measurement of cell viability with MTT assay
A549 cells were transfected with SCCA1 pcDNA expression
vector. Cells were transferred to serum-free media and
treated with 125, 250 or 500 mM H2O2 for 24 h. A modified 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium
bromide (MTT) reduction assay was used to determine the
cell viability.38 Briefly, 65 mg of MTT (SigmaeAldrich Corp,
St Louis, MO) was added to each well and cells were incu-
bated in 5% CO2 for 4 h. Cells were lysed with 100 ml iso-
propanol and absorbance was measured at 550 and 630 nm.
Measurement of apoptosis by annexin V FITC/PI
Transfected A549 cells were treated with 125, 250 or
500 mM H2O2 for 24 h. After 24 h, cell pellets were obtained
by trypsinization, washed with ice cold PBS twice and were
resuspended in ice cold binding buffer at 1  106 cells/ml.
200 ml of cell suspension were stained with annexin FITC
antibody and PI dye using ApopNexin Apoptosis Kit
(Chemicon, MA, USA) and read by flow cytometry (Beckman
Coulter, CA, USA). Annexin positive cells were considered
as early, while annexin and PI double positive cells were
considered as late apoptotic. Cells that stained positively
with PI only were regarded as necrotic.Eosinophils isolation, culture and RT-PCR of SCCA1
Eosinophils were isolated from blood of healthy volunteers
using magnetic selection method (Dynaltech, Oslo,
Norway).29 750  103/ml eosinophils were stimulated with
GM-CSF (20 ng/ml), IL-4 (25 ng/ml), IL-5 (10 ng/ml), IL-13
(25 ng/ml) or their combination. 24 h after incubation at
37 C in 5% CO2, RNA was isolated and reverse transcribed
as outlined above. Previously described SCCA1 specific
primers39 were used for RT-PCR reaction. Products were run
on 2% agarose gel.
Statistical analyses
Statistical analyses were done with SPSS 15 for Windows
(Chicago, IL, USA) and Prism 5 for Windows (GraphPad Soft-
ware Inc., CA, USA). Comparison of quantitative variables
was donewith parametric or non-parametric tests depending
on the normality of distribution. Chi square, ManneWhitney
U or KruskaleWallis test was used for comparison of cate-
gorical and numerical variables as appropriate. Repeated
measures of ANOVA were used to compare cytokine levels,
cell viability and apoptosis. A p value <0.05 was considered
significant. In correcting for multiple comparisons, the p
value was divided by the number of SNPs for the level of
significance. We found that the four SNPs that we describe in
the promoter region of the SCCA1 (see Results) are in perfect
linkage disequilibrium. Therefore,we treated it as one single
SNP and have done the adjustment for multiple comparisons
for two SNPs: one in SCCA1 and one in SCCA2.
In order to adjust for the confounding factors, we used
logistic regression for categorical variables and linear
regression analysis for continuous variables. We examined 6
variables: age, gender, eosinophil count, skin test posi-
tivity, IgE level and SCCA1 genotype. A two-sided p < 0.05
was considered significant.
Results
Characteristics of the study population are summarized in
Table 1. Asthma and atopy related phenotypes including
FEV1, eosinophil counts, skin test positivity and IgE levels
were significantly different between the two groups.
Serum levels of SCCA1 and SCCA2
SCCA1 levels were higher in children with asthma [0.88 ng/
ml (0.57e1.28)] [median (interquartile range)] compared to
controls [0.55 (0.41e0.83)] (p Z 0.011, Mann Whitney U
test) but there was no difference in SCCA2 levels (Fig. 1A
and B). SCCA genotypes had no effect on serum protein
levels (data not shown). There was no correlation between
SCCA1 and SCCA2 levels and clinical parameters such as skin
test positivity, IgE levels, eosinophil numbers, FEV1, and
severity of asthma (data not shown).
Sequencing of SCCA1 and SCCA2 promoter regions
Of the 25 samples from each cases and controls which
would allow us to detect any SNP with a frequency
Table 1 Characteristics of the study population.
Healthy controls Children with asthma p
n Z 191 n Z 442
Age (years)a 10.7 (8.1e13.1) 10.0 (8.1e12.2) >0.05b
Gender
Male (%) 92 (48.2) 240 (54.3) >0.05c
Female (%) 99 (51.8) 202 (45.7)
FEV1 (% predicted)a 101 (91e108) 93 (83e101) <0.001b
Eosinophil count/mm3a 146 (99e274) 260 (150e500) <0.001b
Skin test positivity (%) 31 (16.2) 263 (59.5) <0.001c
IgE (kU/L) a 35 (17e73) 141 (49e472) <0.001b
a Median (interquartile range).
b ManneWhitney U test.
c Chi-square test.
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completed.
We identified five SNPs in the promoter region of
SCCA1; and one SNP at rs3760573 (G/T) in the SCCA2
promoter.
SCCA1 SNPs were coded as 1e5 depending on their
distance from the transcription start site according to the
most recent ensemble sequence [33]: (1) GAAa/gATG
rs118005507, (2) CCTa/gATA rs7240852, (3) CATt/cGGA
rs189633658 and (4) GAGa/gCTT rs116864116 (while this
work was in progress this SNP was assigned an rs number in
the Ensembl genome browser 65 but it does not exist in the
current 67 version). According to the results of sequencing
in 24 cases and controls, the four SNPs (1e4) looked in
linkage disequilibrium. Therefore, in order confirm or
refute, we sequenced further samples from 100 asthmatic
and 100 healthy controls which showed that these four SNPs
are in perfect linkage disequilibrium. LD score was calcu-
lated as 1 (LD 1) by R software for four SNPs in the promoter
region of SCCA1. From these, rs116864116 A/G variation
was chosen to determine the genotype. Hence, the AA
genotype meant the presence of the following genotypes in
other loci: AA at rs118005507, AA at rs7240852 and TT at
rs189633658.Figure 1 Serum levels of SCCA1 (A) and SCCA2 (B) for patienPolymorphism (5) rs60948708 GAGg/aGAG in SCCA1
promoter was found in only one child and was not pursued.
Genotyping for SNPs in the SCCA1 and SCCA2
promoters
There was no difference in the genotype frequencies
between asthmatic individuals and healthy controls (Table
2). However, GG genotype at rs116864116 of the SCCA1
was associated with eosinophil count, skin test positivity
and IgE in the asthmatic population (Table 3). Regression
analysis has shown that SCCA1 genotype is independently
associated only with skin test positivity OR Z 1.427 95%CI
(1.070e1.902, pZ 0.015) but not with eosinophil counts or
IgE levels. SCCA2 genotype was not associated with asthma
or atopy phenotypes (data not shown).
Effects of promoter polymorphisms on SCCA1 gene
expression
Even though the mutant genotype showed slightly higher
promoteractivityacross all conditions, thedifferencebecame
significant only after IL-4 and IL-13 stimulation (Fig. 2).ts and controls. Error bars represent interquartile ranges.
Table 2 SCCA1 (rs116864116) and SCCA2 (rs3760573)
genotypes.
Healthy controls Children with asthma p
SCCA1 genotype
n Z 175 (%) n Z 430 (%)
AA 89 (50.9) 206 (47.9) >0.05a
AG 69 (39.4) 180 (41.9)
GG 17 (9.7) 44 (10.2)
SCCA2 genotype
n Z 145 (%) n Z 177 (%)
GG 9 (6.2) 12 (6.8) >0.05a
GT 55 (37.9) 78 (44.1)
TT 81 (55.9) 87 (49.1)
a Chi-square test.
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GATA-2 and GATA-3 transcription factors showed higher
affinity to the mutant genotype. Stimulation with IL-
4 þ IL-13 basically caused decreased affinity for the
wild genotype and thus resulted in widening of the
difference observed under unstimulated conditions
(Fig. 3). GATA-1 transcription factor did not show any
affinity to either wild or the mutant genotype (data not
shown).
Efficiency of transfection
Transfection efficiency was effectively determined using
both a PCR based technique and Western Blot method
(Supplemental Fig. 1A and B).
Cytokines
IL-1b, INF-g, IL-10, IL-12 were not measurable in A549 cell
culture system. IL-6 and IL-8 levels were significantly
higher in cells transfected with SCCA1 under unstimulated
conditions and after stimulation with IL-4 (p < 0.05),
(Fig. 4A and B). IL-13 treatment with and without IL-4
abolished the increase in transfected cells. RANTES levels
were significantly higher in the supernatants of SCCA1
transfected cells only after IL-4 stimulation (p < 0.05),
(Fig. 4C).Table 3 The effect of SCCA1 genotypes on asthma and atopy p
AA AG
n Z 206 n Z 180
Eosinophil count/mm3a 295 (150e500) 202.5 (150e47)
Skin test positivity (%) 54.4 61.1
IgE (kU/l)a 136 (47e411) 122 (38e448)
a Median (Interquartile range).
b Kruskal Wallis test.
c ManneWhitney U test.
d Chi-square test.Mucus production
MUC5AC expression was significantly lower in transfected
cells under all stimulation conditions (Fig. 5). In addition,
stimulation with NE, IL-4 þ IL-13 and their combination
resulted in a progressive increase in MUC5AC transcription
only in the untransfected cells (Fig. 5).
Cell viability and apoptosis
SCCA1 transfection partially prevented the increase in cell
death and apoptosis induced by increasing doses of H2O2
(Fig. 6AeD).
SCCA1 expression in eosinophils
RNA from A549 cells transfected with SCCA1 vector was
used as a positive control to validate the RT-PCR system. No
SCCA1 transcription could be identified in the eosinophils
regardless of the stimulation (data not shown).
Discussion
Our study shows that the systemic level of SCCA1 is
increased in children with asthma and has profound effects
on the airway epithelium other than protease inhibition
which includes suppression of MUC5AC expression,
increased cell viability, decreased apoptosis, and effects on
the pro-inflammatory cytokines IL-6, IL-8 and RANTES.
Furthermore, our results show that polymorphisms in the
promoter region of SCCA1 are independently associated
with skin test positivity.
The initial finding in our study was a difference in the
SCCA1 serum protein levels between cases and controls.
The genetic arm was designed to account for the observed
difference in systemic protein levels. Therefore, we
restricted our genotyping studies to the promoter region
and did not cover the whole gene. Instead of using pub-
lished databases, we preferred to use sequencing tech-
nology in our population for the determination of genetic
variants for two reasons: the published databases may not
detect some SNPs present in disease specific states and
databases may not reflect population specific SNPs, which,
in this case is Turkish population.
The results of our population study showed that only
SCCA1 but not SCCA2 showed positive associations. Sincehenotypes in asthmatic children.
GG p p
n Z 44 Co-dominant AA þ AG vs GG
400 (192e577) 0.034b 0.038c
75.0 0.033d 0.025d
248 (73e581) >0.05b 0.021c
Figure 2 Promoter reporter assay: A549 cells were transiently transfected with wild type (WV) or mutant type (MV) reporter
vector bearing a 1000 bp promoter region. Reporter activity was normalized by renilla luciferase pRL-TK vector. Open bars
represent wild type and filled bars represent mutant type reporter vector. Basic vector (BV) was used as a control vector for
experiment accuracy. Wild types vector bears AeAeTeA nucleotides and mutant type bears GeGeCeG nucleotides at
rs118005507, rs7240852, rs189633658, rs116864116 respectively. Mean  SEM, N Z 3.
374 C. Karaaslan et al.these two protease inhibitors have different substrate
specificities and distinct biological activities,19 it is not
surprising that they have distinctive roles in the biology of
airway diseases.
SCCA1 and SCCA2 are intracellular proteins. The source
of the SCCA1 protein in plasma is not clear. Although it was
initially suggested that the SCCA1 protein in biological
fluids comes from either cell lysis or leakage,40 Quarta
et al. recently showed that the SCCA1 protein is actively
secreted by transfected cells.41 There is no membrane
receptor described for the SCCA1 protein and the action of
the extracellular SCCA1 protein on the other cells is
unknown. SCCA proteins inhibit serine protease activity
through irreversible suicide substrate-like mechanisms. In
this mechanism serine protease recognizes the serine
protease inhibitor from its reactive center loop (RCL).
Hydroxyl group of serine residue located in the active siteFigure 3 Transcription factor ELISA for GATA-2 and GATA-3 transc
bars represent mutant probes. Wild types vector bears AeAeTeA
rs118005507, rs7240852, rs189633658, rs116864116 respectively. Mof serine protease attacks the RCL and forms a covalent
bond between the active site and RCL. This interaction
changes the conformation and deforms the active site of
serine protease.42
Our study confirms previous studies that have reported
increased systemic levels of the SCCA protein in atopic
diseases such as asthma,25 asthma exacerbation,25,26 atopic
dermatitis24 and allergic rhinitis.27 In our study, we could
not find any association between SCCA protein levels and
clinical parameters. It should be noted, however, that the
levels of the protein is measured in the systemic circulation
but not in the airways or airway tissue in this population
composed of children. Therefore the results need to be
confirmed locally in the airways.
Genetic arm of our study has shown that asthmatic
children carrying the G allele at rs116864116 in the
promoter region of SCCA1 has higher frequency of skin testription factors. Open bars represent wild type probes and filled
nucleotides and mutant type bears GeGeCeG nucleotides at
ean  SEM, N Z 3.
Figure 4 IL-6 (A), IL-8 (B) and RANTES (C) levels released
from A549 cells transfected with empty (open bars) and SCCA1
vector (filled bars) (US Z unstimulated cells, EV Z empty
vector, SCCA1 Z SCCA1 expression vector). Mean  SEM,
N Z 3.
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ported this observation and has shown that it is in fact
independent of other possible confounding factors
including IgE levels and eosinophil counts which may be
associated with allergic diseases. Since previous studies
have shown that systemic levels of SCCA are also elevated
in allergic diseases other than asthma, taken together,
these findings, including our results, suggest that the role of
SCCA1 may not be disease specific but may be important in
a variety of diseases that are related to atopy. On the other
hand, serum levels of SCCA1 are not correlated with the
genotypes in our study. However, since the most likely
source of SCCAs in the extracellular fluid is cellular leakagerelated to cell disruption, the lack of a correlation may be
due to the fact that the protein level in the extracellular
compartment may not actually reflect the amount that is
biologically active.
Our study also provides some mechanistic explanation
regarding the effect of the polymorphisms in the promoter
region. The presence of the G allele at rs116864116 confers
higher promoter activity after stimulation with IL-4 and IL-
13, two cytokines that are known to be elevated in allergic
diseases, thus providing another linkage to the connection
between SCCA1 and atopic diseases. This difference in the
promoter activity may be due to the altered binding affinity
of the transcription factors GATA-2 and GATA-3. The higher
binding affinity of the mutant genotype for both GATA-2
and GATA-3 may also account for the increased promoter
activity in the mutant reporter constructs. Both GATA-2 and
GATA-3 are expressed in epithelial cells.43,44 GATA-3 is an
important activator IL-4, IL-5 and IL-13 and inhibitor of
interferon g.44 This in-vitro observation can provide an
explanation for the consistent association that we observed
between the mutant genotype of the SCCA1 with the atopic
indices such as positive skin testing and high IgE. Even
though there is a clear effect of IL-4 and IL-13 on the
mutant variant that can account for the in-vivo observa-
tions, our results do not provide an explanation for the
observed decrease in the binding affinity of GATA-2 and
GATA-3 to the wild type allele after IL-4 and IL-13 stimu-
lation. One possible explanation may be the presence of
another trans-acting element preventing the binding of
GATA transcription factors to promoter region by binding
this sequence itself. The possibility that the variants in
other parts of the cloned region may be responsible for the
observed difference cannot be excluded.
SCCA1 induced the production IL-6 and IL-8 and RANTES
from the airway epithelium which are activators, attrac-
tants and growth factors for B and T cells, neutrophils,
basophils and eosinophils45e50 .Our results suggest that
SCCA1 can activate almost all cell types that underlie the
inflammation in asthma by increasing the secretion of IL-6,
IL-8 and RANTES from airway epithelium. Interestingly,
SCCA1 induced increase in these cytokines seems to be
abolished by IL-13 even in the presence of IL-4. IL-4 and IL-
13 have overlapping functions but their receptor interac-
tions are different.51 IL-4 and IL-13 receptor complex
comprise of four types receptor chains: IL-13Ra1 and 2, IL-
4Ra, and g together they produce three types of receptor
complexes one of which is common for both cytokines.52
Although IL-13Ra2 chain is accepted as decoy receptor
and regulates IL-13 level, it is also a negative regulator for
IL-4 signaling.53 Depending on the receptor complex, IL-13
cytokine may compete with IL-4 for binding to receptor.54
Therefore, the suppression of IL-6 and IL-8 in the pres-
ence of SCCA1 and IL-13 may be due to a competition for
the receptor and a decrease in the signaling of the IL-4
pathway.
SCCA1 acts differently than other protease inhibitors in
this regard. For example, while non-covalent serine
protease inhibitor benzamidine decreased IL-6, covalent
serine protease inhibitors forskolin, dibutyryl cAMP and 4-
(2-aminoethyl), benzene-sulfonyl fluoride increased IL-6
level in the cell culture supernatants.55 We have recently
shown that SPINK5, a serine protease inhibitor, induces not
Figure 5 RT-PCR results for MUC5AC. Columns represent the band densities of MUC5AC gene/Cyclophilin (NE Z Neutrophil
elastase). Mean  SEM, N Z 3.
376 C. Karaaslan et al.only IL-6 and IL-8 like SCCA1 but also RANTES.37 It seems
that the effects of protease inhibitors are independent
from their protease related functions and can vary from
one molecule to another.
Our results showed that SCCA1 suppresses mucus
production, which is an important factor in the morbidity
and mortality of asthma,56 from the airway epithelium at
the transcriptional level. Thus, the effect of SCCA1 on
mucus production seems to be a protective one in asthma.
This is in contrast to our previous observation that SPINK5
had no effect on mucus production by the airway cells.37
Supporting the previous observations,57,58 our results
suggest SCCA1 protein protects the cells from cell death
induced by H2O2 by decreasing apoptosis. Attenuation of
apoptosis through SCCA1 can occur through its protease
inhibition properties in the upstream of caspase-3
pathway57; or it can occur by a c-Jun NH2-terminalkinase-1 related pathway which is independent from
protease inhibitor activity.58
Taken together, the results of our study suggest that it is
very difficult to assign SCCA either a protective or pro-
pathogenic role in asthma. While certain effects such as up
regulation of IL-6, IL-8 and RANTES by SCCA1 over-
expression appear to be pro inflammatory in asthma, other
effects such as protection against apoptosis and reduction
in mucus production appear to be protective in asthma.
Hence SCCA1 might be regulative effects on asthmatic
complications. Alternatively SCCA1 upregulation may well
be a protective mechanism in asthmatic to lung epithelial
from repeated insults.
It should be noted that the physiological part of our
study was done using A549 cell line which is not an excel-
lent model to reflect the real biological events that in
chronic airway diseases but are commonly used in in-vitro
Figure 6 MTT assay (A and B) and Annexin V/PI staining (C and D) after stimulation with increasing doses of H2O2. Cells are either
transfected with an empty (A and C) or with SCCA1 vector (B and D). USZ unstimulated cells, SCCA1Z SCCA1 expression vector.
Mean  SEM, N Z 3.
The role of squamous cell carcinoma antigen 1 in asthma 377studies. Therefore, the results need to be verified with
primary epithelial cells from asthmatic patients.
To conclude, our study shows that SCCA1 may be an
important mediator in asthma and its actions on the airway
epithelium are not limited to its protease inhibition prop-
erties. It can be protective or inflammatory depending on
extra and intra-cellular signals and may result in quite
diverse physiological outcomes.Conflict of interest statement
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